Compare Adaptive Biotechnologies Corp (ADPT) vs Kraft Heinz Co (KHC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kraft Heinz Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Kraft Heinz Co trades at $25 (market cap $30.00B). The key difference: Kraft Heinz Co is far larger — about 9× Adaptive Biotechnologies Corp's market cap, and Kraft Heinz Co pays a 6.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KHC | |
|---|---|---|
Market Cap | $3.33B | $30.00B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $28.94 |
52-Week Low | $10.24 | $21.21 |
Enterprise Value | $3.19B | $47.04B |
Dividend Yield | — | 6.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Kraft Heinz (KHC) trades at $25.3, down 0.28% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported a net loss of $5.85 billion in 2025, driving negative profit margins, but maintains strong operating cash flow of $4.46 billion and a 6.4% dividend yield. Recent news highlights a global reorganization aimed at accelerating growth and a strategic partnership with Heineken.
KHC presents a mixed outlook: attractive valuation metrics (P/E 13.04, P/B 0.7) and bullish technicals support potential upside, but significant profitability challenges and a cautious analyst consensus (57% hold rating) indicate headwinds. Key risks include execution of the new operating structure and sustained negative earnings, while the high dividend yield offers income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
